New England Journal of Medicine
Published December 4, 2018  (News release from the Ottawa Hospital Research Group will be posted here>)
A low dose of a drug called apixaban provides the first approach to safely prevent blood clots in people with cancer. This is important because venous thromboembolism is the second leading cause of death in cancer patients, and it can also affect quality of life. The researchers estimate this could prevent clots in more than 50,000 cancer patients per year in Canada and the U.S. alone.
Lead author: Marc Carrier, Ottawa Hospital and the University of Ottawa –